To reach more patients across Europe, we're now a part of

Discover more
 emovis-1584.jpg

Homecare Visits

Decentralized Clinical Trials have become a big topic - and not just since Corona. For emovis, the well-being of our patients has been the focus since we were founded, which is why we have been offering homecare visits since 2012 - and thereby significantly improving the situation of certain patients. In 2015, our idea was even awarded the DEN Innovation Prize.

The demand for home visits is high. We now offer this service to CROs and sponsors across the EU (including the UK) and are constantly expanding! Our headquarters are in Berlin, Germany, from where our multicultural team manages our staff scattered all over Europe.

What services do we offer?

The Homecare Visits team will be happy to process and respond to your request. They will inquire about the exact indication, the activities required during the visit, the duration of the study, and the frequency of the visits. In this way, we can advise you on the feasibility of your trial.

The team then prepares all the necessary documentation, from texts for the ethics committee to the training manual for home visit staff and visitation documentation.

In the next step, our team identifies and trains a home visitor in the vicinity of each patient. Only then does our main task begin: We go to the patient to conduct the visit.

Our tasks at a glance:

  • Clarification of time, duration, frequency, and concrete tasks with the client.
  • Recruitment of home visitors, also from the emovis Homecare Visits pool of staff
  • Drafting of contracts and employment of home visitors by the emovis Homecare Visits team
  • Training of homecare workers through the emovis Homecare Visits team

What benefits does Homecare Visits offer you?

  • By including homecare visits in your study, you can include patient populations that would otherwise not be able to participate for a variety of reasons.

    For example, patients who are

    - severely ill and therefore limited in their ability to travel

    - suffering from a rare disease and may live far away from the study site

    - still very young and should not be burdened too much by frequent travelling

    - in the middle of life and do not want to give the disease the space to limit them further by the site visits

  • A larger number of suitable patients can be recruited, regardless of whether they are able to come to the study site.

  • Higher compliance can be achieved, as long travel times often have a negative impact on willingness to participate in studies.

  • Through our extensive customer service, participant retention rate increases.

  • Studies can be conducted on specific indications (some diseases mean that patients are almost unable to leave the house)